AAAAAA

   
Results: 1-21 |
Results: 21
Susceptibility of pneumococci to evernimicin: effect of CO2 and different methodologies
Authors: Hamilton-Miller, JMT Shah, S Loebenberg, D
Citation: Jmt. Hamilton-miller et al., Susceptibility of pneumococci to evernimicin: effect of CO2 and different methodologies, CL MICRO IN, 7(6), 2001, pp. 339-340
EmtA, a rRNA methyltransferase conferring high-level evernimicin resistance
Authors: Mann, PA Xiong, LQ Mankin, AS Chau, AS Mendrick, CA Najarian, DJ Cramer, CA Loebenberg, D Coates, E Murgolo, NJ Aarestrup, FM Goering, RV Black, TA Hare, RS McNicholas, PM
Citation: Pa. Mann et al., EmtA, a rRNA methyltransferase conferring high-level evernimicin resistance, MOL MICROB, 41(6), 2001, pp. 1349-1356
In vitro uptake of SCH 27899 (evernimicin) by rat alveolar macrophages
Authors: Zbaida, S Brieland, J Krieter, P Loebenberg, D Krishna, G Horne, D Lu, XW Yuan, Y Hare, R Cayen, MN Patrick, JE
Citation: S. Zbaida et al., In vitro uptake of SCH 27899 (evernimicin) by rat alveolar macrophages, ANTIM AG CH, 45(3), 2001, pp. 959-961
In vivo activity of evernimicin (SCH 27899) against methicillin-resistant Staphylococcus aureus in experimental infective endocarditis
Authors: Boucher, HW Thauvin-Eliopoulos, C Loebenberg, D Eliopoulos, GM
Citation: Hw. Boucher et al., In vivo activity of evernimicin (SCH 27899) against methicillin-resistant Staphylococcus aureus in experimental infective endocarditis, ANTIM AG CH, 45(1), 2001, pp. 208-211
Novel fungal metabolites as cell wall active antifungals: Fermentation, isolation, physico-chemical properties, structure and biological activity
Authors: Hegde, VR Silver, J Patel, M Gullo, VP Yarborough, R Huang, E Das, PR Puar, MS DiDomenico, BJ Loebenberg, D
Citation: Vr. Hegde et al., Novel fungal metabolites as cell wall active antifungals: Fermentation, isolation, physico-chemical properties, structure and biological activity, J ANTIBIOT, 54(1), 2001, pp. 74-83
Comparison of pathogenesis and host immune responses to Candida glabrata and Candida albicans in systemically infected immunocompetent mice
Authors: Brieland, J Essig, D Jackson, C Frank, D Loebenberg, D Menzel, F Arnold, B DiDomenico, B Hare, R
Citation: J. Brieland et al., Comparison of pathogenesis and host immune responses to Candida glabrata and Candida albicans in systemically infected immunocompetent mice, INFEC IMMUN, 69(8), 2001, pp. 5046-5055
Cytokine networking in lungs of immunocompetent mice in response to inhaled Aspergillus fumigatus
Authors: Brieland, JK Jackson, C Menzel, F Loebenberg, D Cacciapuoti, A Halpern, J Hurst, S Muchamuel, T Debets, R Kastelein, R Churakova, T Abrams, J Hare, R O'Garra, A
Citation: Jk. Brieland et al., Cytokine networking in lungs of immunocompetent mice in response to inhaled Aspergillus fumigatus, INFEC IMMUN, 69(3), 2001, pp. 1554-1560
A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592)
Authors: Manavathu, EK Cutright, JL Loebenberg, D Chandrasekar, PH
Citation: Ek. Manavathu et al., A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592), J ANTIMICRO, 46(2), 2000, pp. 229-234
In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida
Authors: Cacciapuoti, A Loebenberg, D Corcoran, E Menzel, F Moss, EL Norris, C Michalski, M Raynor, K Halpern, J Mendrick, C Arnold, B Antonacci, B Parmegiani, R Yarosh-Tomaine, T Miller, GH Hare, RS
Citation: A. Cacciapuoti et al., In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida, ANTIM AG CH, 44(8), 2000, pp. 2017-2022
SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ("Ramichloridium mackenziei")
Authors: Al-Abdely, HM Najvar, L Bocanegra, R Fothergill, A Loebenberg, D Rinaldi, MG Graybill, JR
Citation: Hm. Al-abdely et al., SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ("Ramichloridium mackenziei"), ANTIM AG CH, 44(5), 2000, pp. 1159-1162
Efficacy of SCH27899 in an animal model of Legionnaires' disease using immunocompromised A/J mice
Authors: Brieland, JK Loebenberg, D Menzel, F Hare, RS
Citation: Jk. Brieland et al., Efficacy of SCH27899 in an animal model of Legionnaires' disease using immunocompromised A/J mice, ANTIM AG CH, 44(5), 2000, pp. 1333-1336
Pharmacokinetics of an everninomicin (SCH 27899) in mice, rats, rabbits, and cynomolgus monkeys following intravenous administration
Authors: Lin, C Gupta, S Loebenberg, D Cayen, MN
Citation: C. Lin et al., Pharmacokinetics of an everninomicin (SCH 27899) in mice, rats, rabbits, and cynomolgus monkeys following intravenous administration, ANTIM AG CH, 44(4), 2000, pp. 916-919
Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys
Authors: Nomeir, AA Kumari, P Hilbert, MJ Gupta, S Loebenberg, D Cacciapuoti, A Hare, R Miller, GH Lin, CC Cayen, MN
Citation: Aa. Nomeir et al., Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys, ANTIM AG CH, 44(3), 2000, pp. 727-731
Efficacy of SCH56592 in a rabbit model of invasive aspergillosis
Authors: Kirkpatrick, WR McAtee, RK Fothergill, AW Loebenberg, D Rinaldi, MG Patterson, TF
Citation: Wr. Kirkpatrick et al., Efficacy of SCH56592 in a rabbit model of invasive aspergillosis, ANTIM AG CH, 44(3), 2000, pp. 780-782
Evernimicin (SCH27899) inhibits a novel ribosome target site: Analysis of 23S ribosomal DNA mutants
Authors: Adrian, PV Mendrick, C Loebenberg, D McNicholas, P Shaw, KJ Klugman, KP Hare, RS Black, TA
Citation: Pv. Adrian et al., Evernimicin (SCH27899) inhibits a novel ribosome target site: Analysis of 23S ribosomal DNA mutants, ANTIM AG CH, 44(11), 2000, pp. 3101-3106
Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice
Authors: Connolly, P Wheat, LJ Schnizlein-Bick, C Durkin, M Kohler, S Smedema, M Goldberg, J Brizendine, E Loebenberg, D
Citation: P. Connolly et al., Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice, ANTIM AG CH, 44(10), 2000, pp. 2604-2608
Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts
Authors: Molina, J Martins, O Brener, Z Romanha, AJ Loebenberg, D Urbina, JA
Citation: J. Molina et al., Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts, ANTIM AG CH, 44(1), 2000, pp. 150-155
Immunomodulatory role of endogenous interleukin-18 in gamma interferon-mediated resolution of replicative Legionella pneumophila lung infection
Authors: Brieland, JK Jackson, C Hurst, S Loebenberg, D Muchamuel, T Debets, R Kastelein, R Churakova, T Abrams, J Hare, R O'Garra, A
Citation: Jk. Brieland et al., Immunomodulatory role of endogenous interleukin-18 in gamma interferon-mediated resolution of replicative Legionella pneumophila lung infection, INFEC IMMUN, 68(12), 2000, pp. 6567-6573
Treatment of murine fusariosis with SCH 56592
Authors: Lozano-Chiu, M Arikan, S Paetznick, VL Anaissie, EJ Loebenberg, D Rex, JH
Citation: M. Lozano-chiu et al., Treatment of murine fusariosis with SCH 56592, ANTIM AG CH, 43(3), 1999, pp. 589-591
Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice
Authors: Connolly, P Wheat, J Schnizlein-Bick, C Durkin, M Kohler, S Smedema, M Goldberg, J Brizendine, E Loebenberg, D
Citation: P. Connolly et al., Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice, ANTIM AG CH, 43(2), 1999, pp. 322-328
Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases
Authors: Al-Abdely, HM Graybill, JR Loebenberg, D Melby, PC
Citation: Hm. Al-abdely et al., Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases, ANTIM AG CH, 43(12), 1999, pp. 2910-2914
Risultati: 1-21 |